Mapping SARS-CoV-2 antigenic relationships and serological responses
Open accessPublished version of a preprint
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
During the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, multiple variants escaping preexisting immunity emerged, causing reinfections of previously exposed individuals. Here, we used antigenic cartography to analyze patterns of cross-reactivity among 21 variants and 15 groups of human sera obtained after primary infection with 10 different variants or after messenger RNA (mRNA)–1273 or mRNA-1273.351 vaccination. We found antigenic differences among pre-Omicron variants caused by substitutions at spike-protein positions 417, 452, 484, and 501. Quantifying changes in response breadth over time and with additional vaccine doses, our results show the largest increase between 4 weeks and >3 months after a second dose. We found changes in immunodominance of different spike regions, depending on the variant an individual was first exposed to, with implications for variant risk assessment and vaccine-strain selection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimation of Relationships for Limited Dependent Variables
Tobin, J. (1958) · Econometrica · doi:10.2307/1907382 · Cited by 6,996
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923 · cited 1×
“The derivation of the cell line is described in ( 62 ).”
BackgroundKorber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281 · cited 1×
“During the first year of the pandemic, circulation was dominated by the B.1 variant, characterized by the D614G substitution in the spike protein, which imparted increased infectivity and transmissibility in vitro and in animal models ( 2 , 3 ) but did not escape serum neutralization ( 4 ).”
BackgroundSelf-citationAn mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312 · cited 1×
“Theimpactofsubstitutionsat position484,417,and501agreewithother workbasedondeepmutationalscanning(DMS) ( 37 – 39 ) and neutralization data from vesicular stomatitis virus pseudotyped particles ( 40 , 41 ).”
BackgroundOmicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
Cao, Y., Wang, J., Jian, F., Xiao, T., Song, W., Yisimayi, A., Huang, W., Li, Q., Wang, P., An, R., et al. (2022) · Nature · doi:10.1038/s41586-021-04385-3 · Cited by 2,006
Mapping the Antigenic and Genetic Evolution of Influenza Virus
Smith, D. J., Lapedes, A. S., de Jong, J. C., Bestebroer, T. M., Rimmelzwaan, G. F., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2004) · Science · doi:10.1126/science.1097211 · Cited by 1,868 · cited 2×
“Antigenic cartography ( 13 ) is a tool originally developed for the analysis of human seasonal influenza virus antigenic data and has since been used in the analysis of antigenic variation in other pathogens, including avian, equine, and swine influenza viruses ( 14 – 18 ); flaviviruses ( 19 ),…”
Self-citationSafety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523 · cited 1×
“The phase 1 study protocols and results are reported previously (57, 58).”
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
Garcia-Beltran, W. F., Lam, E. C., St. Denis, K., Nitido, A. D., Garcia, Z. H., Hauser, B. M., Feldman, J., Pavlovic, M. N., Gregory, D. J., Poznansky, M. C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.013 · Cited by 1,353
Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
Liu, L., Iketani, S., Guo, Y., Chan, J. F.-W., Wang, M., Liu, L., Luo, Y., Chu, H., Huang, Y., Nair, M. S., et al. (2022) · Nature · doi:10.1038/s41586-021-04388-0 · Cited by 1,290
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
Choi, B., Choudhary, M. C., Regan, J., Sparks, J. A., Padera, R. F., Qiu, X., Solomon, I. H., Kuo, H.-H., Boucau, J., Bowman, K., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2031364 · Cited by 1,246
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
Dejnirattisai, W., Huo, J., Zhou, D., Zahradník, J., Supasa, P., Liu, C., Duyvesteyn, H. M. E., Ginn, H. M., Mentzer, A. J., Tuekprakhon, A., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.046 · Cited by 930 · cited 1×
“All variants in the Omicron lineage show substantial escape from postvaccination and convalescent sera after infection with the pre-Omicron variants ( 11 , 12 ).”
BackgroundSelf-citationSARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo
Hou, Y. J., Chiba, S., Halfmann, P., Ehre, C., Kuroda, M., Dinnon, K. H., Leist, S. R., Schäfer, A., Nakajima, N., Takahashi, K., et al. (2020) · Science · doi:10.1126/science.abe8499 · Cited by 900 · cited 1×
“During the first year of the pandemic, circulation was dominated by the B.1 variant, characterized by the D614G substitution in the spike protein, which imparted increased infectivity and transmissibility in vitro and in animal models ( 2 , 3 ) but did not escape serum neutralization ( 4 ).”
BackgroundSelf-citationNaturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection
Wang, Z., Muecksch, F., Schaefer-Babajew, D., Finkin, S., Viant, C., Gaebler, C., Hoffmann, H. H., Barnes, C. O., Cipolla, M., Ramos, V., et al. (2021) · Nature · doi:10.1038/s41586-021-03696-9 · Cited by 721
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
Liu, C., Ginn, H. M., Dejnirattisai, W., Supasa, P., Wang, B., Tuekprakhon, A., Nutalai, R., Zhou, D., Mentzer, A. J., Zhao, Y., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.020 · Cited by 669
A Bivalent Omicron-Containing Booster Vaccine against Covid-19
Chalkias, S., Harper, C., Vrbicky, K., Walsh, S. R., Essink, B., Brosz, A., McGhee, N., Tomassini, J. E., Chen, X., Chang, Y., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2208343 · Cited by 627 · cited 1×
“…analyses and antibody land-scapestoanalyzeimmuneresponsesinvaccination sera taken at multiple time points after vaccination, we quantified and visualized changes in responsecross-reactivitybreadth,disentangling it from changes in cross-reactivity that are due to differences in response…”
Self-citationReduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
Supasa, P., Zhou, D., Dejnirattisai, W., Liu, C., Mentzer, A. J., Ginn, H. M., Zhao, Y., Duyvesteyn, H. M. E., Nutalai, R., Tuekprakhon, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.033 · Cited by 460 · cited 1×
“Within SARS-CoV-2, our findings are consistent with studies showing that monoclonal antibodies tend to have different regional binding preferences when sourced from individuals exposed to different variants ( 10 , 49 – 51 ).”
Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies
Greaney, A. J., Starr, T. N., Barnes, C. O., Weisblum, Y., Schmidt, F., Caskey, M., Gaebler, C., Cho, A., Agudelo, M., Finkin, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24435-8 · Cited by 433 · cited 1×
“Theimpactofsubstitutionsat position484,417,and501agreewithother workbasedondeepmutationalscanning(DMS) ( 37 – 39 ) and neutralization data from vesicular stomatitis virus pseudotyped particles ( 40 , 41 ).”
BackgroundStructural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants
Yuan, M., Huang, D., Lee, C.-C. D., Wu, N. C., Jackson, A. M., Zhu, X., Liu, H., Peng, L., van Gils, M. J., Sanders, R. W., et al. (2021) · doi:10.1101/2021.02.16.430500 · Cited by 364 · cited 1×
“Becauseithasbeenshown that the presence of the K417N substitution alone in the absence of 501Y greatly reduces angiotensin-converting enzyme 2 (ACE2) affi-nityinsomecontexts ( 31 ),wespeculatethatthe effectseeninB.1.429+ K417Nmaybeinfluenced byanartificialinflationoftitersgenerally.”
BackgroundInfluentialD614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization
Weissman, D., Alameh, M.-G., de Silva, T., Collini, P., Hornsby, H., Brown, R., LaBranche, C. C., Edwards, R. J., Sutherland, L., Santra, S., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2020.11.012 · Cited by 324 · cited 1×
“1 variant, characterized by the D614G substitution in the spike protein, which imparted increased infectivity and transmissibility in vitro and in animal models (2, 3) but did not escape serum neutralization (4).”
BackgroundSelf-citationImprinted antibody responses against SARS-CoV-2 Omicron sublineages
Park, Y.-J., Pinto, D., Walls, A. C., Liu, Z., De Marco, A., Benigni, F., Zatta, F., Silacci-Fregni, C., Bassi, J., Sprouse, K. R., et al. (2022) · doi:10.1101/2022.05.08.491108 · Cited by 251
Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity
Lucas, C., Vogels, C. B. F., Yildirim, I., Rothman, J. E., Lu, P., Monteiro, V., Gehlhausen, J. R., Campbell, M., Silva, J., Tabachnikova, A., et al. (2021) · Nature · doi:10.1038/s41586-021-04085-y · Cited by 226
Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct
Mykytyn, A. Z., Rissmann, M., Kok, A., Rosu, M. E., Schipper, D., Breugem, T. I., van den Doel, P. B., Chandler, F., Bestebroer, T., de Wit, M., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abq4450 · Cited by 153 · cited 1×
“Basedonthelargeantigenicdiffer-encebetweenD614GandBA.1andthetypes ofreactivityseeninmorecontrolledanimal-modelBA.1infections( 63 ), we judged the four more-BA.1-specific sera to be likely first infections and excluded the rest of the group as likely cases that had had a previous exposure to a…”
BackgroundSelf-citationRapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant
Lyke, K. E., Atmar, R. L., Islas, C. D., Posavad, C. M., Szydlo, D., Paul Chourdhury, R., Deming, M. E., Eaton, A., Jackson, L. A., Branche, A. R., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100679 · Cited by 153
Self-citationProtective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains
Ying, B., Whitener, B., VanBlargan, L. A., Hassan, A. O., Shrihari, S., Liang, C.-Y., Karl, C. E., Mackin, S., Chen, R. E., Kafai, N. M., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abm3302 · Cited by 85
Self-citationWang, W., Lusvarghi, S., Subramanian, R., Epsi, N. J., Wang, R., Goguet, E., Fries, A. C., Echegaray, F., Vassell, R., Coggins, S., et al. (2022) · doi:10.1101/2022.07.05.498883 · Cited by 68
Research works printed but not linked: 49
- 10.1016/S2666-5247(22)00384-6 · DOI
- 10.1016/j.cell.2021.04.006 · DOI · Paper page
- 10.1038/s41564-021-00974-0 · DOI
- A. Netzl S. Tureli E. LeGresley B. Mühlemann S. H. Wilks D. J. Smith Analysis of SARS-CoV-2 Omicron Neutralization Data up to 2021-12-22. bioRxiv 2021.12.31.474032 [Preprint] (2022). 10.1101/2021.12.31.474032 · DOI
- 10.1637/11087-041015-Reg · DOI
- 10.1016/j.vetmic.2013.11.039 · DOI
- 10.1186/s12859-018-2042-4 · DOI
- 10.1038/s41598-021-90512-z · DOI
- 10.3389/fmicb.2021.662028 · doi:10.3389/fmicb.2021.662028
- 10.1016/j.meegid.2018.11.023 · doi:10.1016/j.meegid.2018.11.023
- 10.1126/science.aac5017 · DOI · Paper page
- 10.1126/science.abk0058 · DOI
- 10.1099/vir.0.065953-0 · DOI
- 10.1099/vir.0.057521-0 · DOI
- 10.1016/j.chom.2021.06.009 · DOI
- 10.1016/j.celrep.2022.111496 · DOI
- 10.1093/cid/ciaa979 · DOI · Paper page
- 10.1016/j.chom.2022.10.012 · DOI
- 10.1038/s41467-022-35312-3 · DOI
- 10.1126/science.abh1139 · doi:10.1126/science.abh1139 · Paper page
- 10.1016/j.celrep.2021.110218 · DOI · Paper page
- 10.3390/v14092061 · DOI
- 10.1126/science.1256427 · DOI · Paper page
- A. R. Branche N. G. Rouphael D. J. Diemert A. R. Falsey C. Losada L. R. Baden S. E. Frey J. A. Whitaker S. J. Little E. J. Anderson E. B. Walter R. M. Novak R. Rupp L. A. Jackson T. M. Babu A. C. Kottkamp A. F. Luetkemeyer L. C. Immergluck R. M. Presti M. Bäcker P. L. Winokur S. M. Mahgoub P. A. Goepfert D. N. Fusco E. Malkin J. M. Bethony E. E. Walsh D. S. Graciaa H. Samaha A. C. Sherman S. R. Walsh G. Abate Z. Oikonomopoulou H. M. El Sahly T. C. S. Martin C. A. Rostad M. J. Smith B. G. Ladner L. Porterfield M. Dunstan A. Wald T. Davis R. L. Atmar M. J. Mulligan K. E. Lyke C. M. Posavad M. A. Meagher D. S. Stephens K. M. Neuzil K. Abebe H. Hill J. Albert T. C. Lewis L. A. Giebeig A. Eaton A. Netzl S. H. Wilks S. Türeli M. Makhene S. Crandon M. Lee S. U. Nayak D. C. Montefiori M. Makowski D. J. Smith P. C. Roberts J. H. Beigel COVAIL Study Group SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses. medRxiv 2022.07.12.22277336 [Preprint] (2022). .10.1101/2022.07.12.22277336 · DOI
- 10.1371/journal.ppat.1010248 · DOI
- 10.1126/science.1244730 · DOI · Paper page
- 10.1128/JVI.05319-11 · DOI
- 10.1128/JVI.03805-13 · DOI
- 10.1016/j.jhep.2019.11.011 · doi:10.1016/j.jhep.2019.11.011
- 10.1016/j.celrep.2022.110689 · DOI
- 10.1371/journal.pone.0041895 · DOI
- 10.1016/j.xcrm.2021.100225 · DOI · Paper page
- 10.1016/j.cell.2021.02.037 · DOI · Paper page
- 10.1016/j.chom.2021.11.013 · DOI
- 10.1126/sciimmunol.abq2427 · DOI · Paper page
- 10.1126/sciimmunol.ade2283 · DOI
- 10.1126/sciimmunol.abq3511 · DOI
- 10.1126/science.adc9127 · DOI · Paper page
- S. H. Wilks acorg/mapping_SARS-CoV-2_antigenic_relationships_and_serological_responses: Mapping SARS-CoV-2 antigenic relationships and serological responses first release Version 1.0.0 Zenodo (2023); 10.5281/zenodo.8195839 · DOI
- 10.1016/j.chom.2021.03.002 · DOI · Paper page
- N. A. Doria-Rose X. Shen S. D. Schmidt S. O’Dell C. McDanal W. Feng J. Tong A. Eaton M. Maglinao H. Tang K. E. Manning V.-V. Edara L. Lai M. Ellis K. Moore K. Floyd S. L. Foster R. L. Atmar K. E. Lyke T. Zhou L. Wang Y. Zhang M. R. Gaudinski W. P. Black I. Gordon M. Guech J. E. Ledgerwood J. N. Misasi A. Widge P. C. Roberts J. Beigel B. Korber R. Pajon J. R. Mascola M. S. Suthar D. C. Montefiori Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization. medRxiv 2021.12.15.21267805 [Preprint] (2021). https://doi.org/10.1101/2021.12.15.21267805.10.1101/2021.12.15.21267805 · DOI
- 10.1080/00401706.1963.10490102 · DOI · Paper page
- 10.1016/j.biologicals.2005.09.001 · doi:10.1016/j.biologicals.2005.09.001
- J. Kruskal M. Wish Multidimensional Scaling (Sage 1978). · DOI · Paper page
- 10.1145/279232.279236 · DOI · Paper page
- S. H. Wilks “Visualisation and analysis of patterns in serological data using ‘antibody landscapes ’” thesis Univ. of Cambridge (2018).
- 10.1038/s41467-022-31556-1 · DOI
- 10.1016/j.chom.2022.04.014 · DOI
- 10.1016/j.immuni.2022.07.018 · DOI
Cited by
Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants
Wang, Q., Iketani, S., Li, Z., Liu, L., Guo, Y., Huang, Y., Bowen, A. D., Liu, M., Wang, M., Yu, J., et al. (2023) · Cell · doi:10.1016/j.cell.2022.12.018 · Cited by 912
Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and Monoclonal Antibodies
Wilhelm, A., Widera, M., Grikscheit, K., Toptan, T., Schenk, B., Pallas, C., Metzler, M., Kohmer, N., Hoehl, S., Helfritz, F. A., et al. (2021) · doi:10.1101/2021.12.07.21267432 · Cited by 440
Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct
Mykytyn, A. Z., Rissmann, M., Kok, A., Rosu, M. E., Schipper, D., Breugem, T. I., van den Doel, P. B., Chandler, F., Bestebroer, T., de Wit, M., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abq4450 · Cited by 153
Self-citationWang, W., Lusvarghi, S., Subramanian, R., Epsi, N. J., Wang, R., Goguet, E., Fries, A. C., Echegaray, F., Vassell, R., Coggins, S., et al. (2022) · doi:10.1101/2022.07.05.498883 · Cited by 68
Metadata
- Authors
- Wilks, S. H., Mühlemann, B., Shen, X., Türeli, S., LeGresley, E. B., Netzl, A., Caniza, M. A., Chacaltana-Huarcaya, J. N., Corman, V. M., Daniell, X., Datto, M. B., Dawood, F. S., Denny, T. N., Drosten, C., Fouchier, R. A. M., Garcia, P. J., Halfmann, P. J., Jassem, A., Jeworowski, L. M., Jones, T. C., Kawaoka, Y., Krammer, F., McDanal, C., Pajon, R., Simon, V., Stockwell, M. S., Tang, H., van Bakel, H., Veguilla, V., Webby, R., Montefiori, D. C., & Smith, D. J.
- Venue
- Science
- Published
- 2023-10-06
- Volume
- 382
- Issue
- 6666
- Pages
- eadj0070-eadj0070
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W4387392387
- Cited by
- 145
- References
- 26
- FWCI
- 20.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.